Send to

Choose Destination
Eur Heart J Suppl. 2019 Feb;21(Suppl A):A41-A47. doi: 10.1093/eurheartj/suy031. Epub 2019 Feb 26.

New treatments for hyperkalaemia: clinical use in cardiology.

Author information

Department of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY, USA.
Department of Medicine, University of Mississippi, 2500 North State Street, Jackson, MS, USA.
Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany; and.
Department of Cardiology, Universityätsmedizin Göttingen (UMG), Göttingen, Germany.


Hyperkalaemia causes significant burden, and even mild hyperkalaemia has been independently associated with increased morbidity and mortality. Patients with chronic disease states, such as heart failure, hypertension, chronic kidney disease and diabetes mellitus, are increasingly susceptible to the development of hyperkalaemia. Options for management of hyperkalaemia had mainly been limited to short-term, temporizing methods with focus on rapid achievement of normokalaemia. Until recently, there was a lack of safe, efficacious and well-tolerated therapies for long-term management. Two novel potassium binders, patiromer and sodium zirconium cyclosilicate, have recently been approved by the US Food and Drug Administration for the management of hyperkalaemia. This review discusses these potassium binders with focus largely on the clinical implications of these agents in patients with chronic cardiovascular conditions.


Heart failure; Hyperkalaemia; Hypertension; Patiromer; Sodium zirconium cyclosilicate

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center